Senate Hearing on Prescription Drug Costs and Innovation
January 1, 2019
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This hearing served as a formal review of federal policy proposals intended to lower out-of-pocket prescription drug costs for consumers and influence the future of pharmaceutical market regulations.
Potentially affected actors named in the source documents. Mention is not a position.
Patients
The proposed policies aim to change out-of-pocket costs and access to prescription medications.
Pharmaceutical Industry
Policy changes regarding drug pricing and patent terms directly impact the business models and innovation incentives for drug manufacturers.
Health Insurance Providers
Insurance plans are involved in the administration of drug benefits and pricing negotiations.
Last recorded activity January 1, 2019.
Next step not available in the current record.
Summary
Key Facts
- The hearing was held on June 26, 2018, in the Dirksen Senate Office Building.
- The primary subject was the Trump administration's 'blueprint' for lowering prescription drug costs.
- Secretary of Health and Human Services Alex Azar provided testimony on the administration's policy goals.
- The committee discussed the balance between drug affordability and the need for continued pharmaceutical innovation.
- The hearing included input from various stakeholders, including health insurance plans, hospital associations, and pharmacy organizations.
- Chairman Hatch emphasized the historical context of the Hatch-Waxman Act in current drug pricing discussions.
Why It Matters
This hearing served as a formal review of federal policy proposals intended to lower out-of-pocket prescription drug costs for consumers and influence the future of pharmaceutical market regulations.
Frequently Asked Questions
What was the purpose of this hearing?
Who testified at this hearing?
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on Drug Affordability
The hearing highlights a shift toward federal intervention in drug pricing through administrative blueprints rather than solely relying on market forces.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools